Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone (NCT00000588) | Clinical Trial Compass
CompletedPhase 2
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
120 participantsStarted 1989-06-05
Plain-language summary
To demonstrate the safety and effectiveness of orally-administered pyridoxal isonicotinoyl hydrazone (PIH) for the chronic treatment of iron overload.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients meeting any of the following health conditions and eligible for Chronic PIH Treatment
* Non- transfusion-dependent patients with iron-loading anemias
* Transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine
* Iron-loaded, transfusion-dependent patients
* Ages: 18-75 years old
Exclusion Criteria:
* People who are not eligible for chronic PIH therapy and not meet the medical conditions listed in the Inclusion criteria
* Ages: 17 years old or younger or 76 years old or older